Forian Inc (FORA)

In March 2026, Forian Inc. announced its fourth quarter and full year 2025 financial results, reported its first-quarter EPS of $-0.060, missing analyst estimates, and experienced a decrease in short interest. The stock price declined over the preceding year but rose slightly compared to the previous week. In November 2025, Forian Inc. announced its third-quarter 2025 financial results, reporting a 66% year-over-year increase in revenue and reaffirmed its full-year 2025 revenue guidance. In August 2025, Forian Inc. announced that its Board of Directors had received an unsolicited, preliminary, non-binding proposal letter from its CEO to take the company private.

Information regarding the specific demand seasonality for Forian, Inc.'s products and services is not explicitly available. The company's offerings are primarily subscription and services-based data management and analytics solutions for the life science, healthcare, and financial services industries, suggesting a potentially more stable demand pattern rather than strong seasonality.

Forian, Inc. is a publicly traded health technology company providing data science-driven information and analytics solutions to optimize performance for customers in life science, healthcare, and financial services. The company's offerings include data management capabilities, Real World Evidence (RWE), market access solutions, and proprietary data-driven insights, utilizing platforms like CHRONOS, Chartis, Kyber Data Science, and the Data Factory. Forian's solutions are subscription and services-based, leveraging a large HIPAA-compliant U.S. health data repository.

Forian, Inc. is headquartered in Newtown, Pennsylvania, United States. The company's cloud-based data centers, which manage its data ingestion, transformation, and delivery services, along with its business intelligence platforms, are also located within the United States, indicating a primary operational and market focus within the U.S.

Forian aims to improve health outcomes and business value through data, positioning itself as a pioneering healthtech firm with an integrated SOC-2 / HIPAA-compliant platform. However, its reputation has been affected by dependence on third-party data suppliers, a material weakness in internal control over financial reporting related to revenue recognition, and the CEO's proposal to take the company private.

Forian Inc.'s ownership is concentrated among insiders (61.26%), with institutional shareholders holding 13.00% and retail investors holding 25.74%. Major institutional owners include Oracle Investment Management Inc., Staley Capital Advisers Inc., and Vanguard Group Inc. Key individual owners include Adam H. Dublin, Wygod Family Dynasty Trust Max, and Max C. Wygod.